UroGen Pharma Files 8-K on Operations
Ticker: URGN · Form: 8-K · Filed: 2024-08-13T00:00:00.000Z
Sentiment: neutral
Topics: operations, financials, sec-filing
Related Tickers: URGN
TL;DR
UroGen Pharma dropped an 8-K update on financials and operations, check it for the latest.
AI Summary
UroGen Pharma Ltd. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, but does not detail specific financial figures or operational outcomes within the provided text.
Why It Matters
This filing indicates UroGen Pharma is providing updates on its financial performance and operational status to the SEC, which is crucial for investors to assess the company's health.
Risk Assessment
Risk Level: low — The filing is a standard operational update and does not contain information suggesting immediate or significant risk.
Key Players & Entities
- UroGen Pharma Ltd. (company) — Registrant
- August 13, 2024 (date) — Date of earliest event reported
- 001-38079 (company) — SEC File Number
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text of the 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits,' but does not specify the actual financial figures or operational outcomes.
When was this 8-K filing submitted to the SEC?
The filing was submitted on August 13, 2024, as indicated by the 'Date of Report (Date of earliest event reported)' and 'FILED AS OF DATE'.
What is UroGen Pharma Ltd.'s principal executive office address?
The address of UroGen Pharma Ltd.'s principal executive offices is 400 Alexander Park Drive, 4th Floor, Princeton, New Jersey, 08540.
What is the company's telephone number?
The registrant's telephone number, including area code, is +1 (646) 768-9780.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 498 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-08-13 08:01:59
Filing Documents
- d865545d8k.htm (8-K) — 25KB
- d865545dex991.htm (EX-99.1) — 78KB
- 0001193125-24-199425.txt ( ) — 237KB
- urgn-20240813.xsd (EX-101.SCH) — 3KB
- urgn-20240813_lab.xml (EX-101.LAB) — 18KB
- urgn-20240813_pre.xml (EX-101.PRE) — 11KB
- d865545d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Press Release dated August 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 13, 2024 UROGEN PHARMA LTD. By: /s/ Don Kim Don Kim Chief Financial Officer